CAS 1151516-14-1

Lesinurad sodium

CAS: 1151516-14-1

Sodium 2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetate

Formel: C₁₇H₁₃BrN₃NaO₂S

Reinheit: 98%

Molekulargewicht: 426.26

Ref: IN-DG332954

Lesinurad Sodium

CAS: 1151516-14-1

Lesinurad Sodium

Formel: C₁₇H₁₃BrN₃NaO₂S

Reinheit: 98%

Molekulargewicht: 426.26

Ref: 54-OR1027806

Acetic acid, 2-[[5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-, sodium salt (1:1)

CAS: 1151516-14-1

Formel: C₁₇H₁₃BrN₃NaO₂S

Reinheit: 98%

Farbe und Form: Solid

Molekulargewicht: 426.2628

Ref: IN-DA000GBQ

Lesinurad sodium

CAS: 1151516-14-1

Lesinurad sodium

Formel: C₁₇H₁₃BrN₃NaO₂S

Reinheit: ≥98%

Molekulargewicht: 426.26

Ref: 54-BUP01878

Lesinurad sodium

CAS: 1151516-14-1

Lesinurad sodium (RDEA594 sodium) is a selective inhibitor of uric acid reabsorption and is used in the study of cardiovascular diseases.

Formel: C₁₇H₁₃BrN₃NaO₂S

Reinheit: 99.97%

Farbe und Form: Solid

Molekulargewicht: 426.26

Ref: TM-T21301

Lesinurad sodium

CAS: 1151516-14-1

Lesinurad sodium is a prodrug that is hydrolyzed to form ethyl formate, which inhibits the acid transporter (NT) in the kidneys. It is used for the treatment of chronic gouty arthritis and hyperuricemia associated with the use of xanthine oxidase inhibitors or allopurinol. Lesinurad sodium has been shown to be effective in reducing serum uric acid levels and pain symptoms in patients with chronic gouty arthritis. The drug has a plasma concentration-time curve that follows first-order kinetics and an elimination half-life of 15 hours. Lesinurad sodium has been shown to inhibit NT activity by structural formula, reaction yield, introducing techniques, and pharmacodynamics.

Formel: C₁₇H₁₃BrN₃O₂S·Na

Reinheit: Min. 95%

Molekulargewicht: 426.27 g/mol

Ref: 3D-BWB51614